专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10745728B1 Applications for biversal nucleoside analogs 有权
公开(公告)号：US10745728B1
公开(公告)日：2020-08-18
申请号：US16113766
申请日：2018-08-27
申请人： Steven A Benner , Hyo-Joong Kim , Zunyi Yang
发明人： Steven A Benner , Hyo-Joong Kim , Zunyi Yang
IPC分类号： C07H19/00 , C07H21/00 , C12P19/34 , C12Q1/686 , C07H19/04 , C07H21/02 , C07H21/04
摘要： This invention relates to the use of analogs of purines that have two tautomeric forms, one formally complementary to thymidine, the other formally complementary to cytidine, and analogs of pyrimidines that have two tautomeric forms, one formally complementary to guanosine, the other formally complementary to adenosine. These uses include the polymerase chain reaction amplification of targets having polymorphisms in primer binding sites and ligation.

2. 发明授权

US08389703B1 Ribonucleoside analogs with novel hydrogen bonding patterns 有权
标题翻译：具有新型氢键模式的核糖核苷类似物
公开(公告)号：US08389703B1
公开(公告)日：2013-03-05
申请号：US13287169
申请日：2011-11-02
申请人： Steven A. Benner , Hyo-Joong Kim
发明人： Steven A. Benner , Hyo-Joong Kim
IPC分类号： C07H19/048 , C07H21/00 , C07H21/02
CPC分类号： C07D405/04 , C12P19/34
摘要： This invention relates to nucleoside, nucleotide, and oligonucleotide analogs that incorporate non-standard nucleobase analogs, defined to be those that present a pattern of hydrogen bonds to a paired nucleobase analog in a complementary strand that is different from the pattern presented by adenine, guanine, cytosine, and thymine. The invention is specifically concerned with nucleotide analogs that present the donor-donor-acceptor, hydrogen bonding patterns on pyrimidine analogs, and especially those that are analogs of ribonucleotides, including protected ribonucleotides suitable for phosphoramidite-based synthesis of RNA. The heterocycles on these nucleoside analogs are aminopyridones that have electron withdrawing groups attached to the position analogous to the 5-position of the ring in standard pyrimidines, including nitro, cyano, and carboxylic acid derivatives.
摘要翻译：本发明涉及包含非标准核碱基类似物的核苷，核苷酸和寡核苷酸类似物，其被定义为与互补链中的配对核碱基类似物呈现氢键图案的不同于腺嘌呤，鸟嘌呤，胞嘧啶和胸腺嘧啶。本发明特别涉及呈现供体 - 供体受体的核苷酸类似物，嘧啶类似物上的氢键型，特别是涉及核糖核苷酸类似物的核苷酸类似物，包括适合于基于亚磷酰胺的RNA合成的受保护的核糖核苷酸。这些核苷类似物上的杂环是在标准嘧啶（包括硝基，氰基和羧酸衍生物）中具有连接到类似于环的5位的位置的吸电子基团的氨基吡啶酮。

3. 发明授权

US10059735B1 Nucleoside heterocycle that binds to both thymidine and cytidine 有权
公开(公告)号：US10059735B1
公开(公告)日：2018-08-28
申请号：US15377236
申请日：2016-12-13
申请人： Steven A Benner , Hyo-Joong Kim
发明人： Steven A Benner , Hyo-Joong Kim
IPC分类号： C07H19/22 , C07H19/24 , C07H21/04 , C07H21/02 , C07H19/04 , C07H19/23
CPC分类号： C07H19/24 , C07H19/04 , C07H19/23 , C07H21/00 , C07H21/02 , C07H21/04
摘要： This application discloses nucleoside analogs that when incorporated into a oligonucleotide, forms a nucleobase pair with either thymidine or cytidine that are present in a complementary strand at the paired position. These analogs are called “purine biversals”. Such compounds and their associated processes have utility in processes that detect complementary oligonucleotides, in particular oligonucleotides from natural sources and in complex biological mixtures, where the sequence of the complementary oligonucleotide being detected is not known precisely. The invention also includes compositions of matter that are oligonucleotides that contain purine biversals of the instant invention, and duplexes of said oligonucleotides.

4. 发明授权

US11168106B1 Synthesis and stabilization of nicotinamide ribose and its derivatives 有权
公开(公告)号：US11168106B1
公开(公告)日：2021-11-09
申请号：US16160189
申请日：2018-10-15
申请人： Hyo-Joong Kim , Steven A Benner , Ion Mircesti Scorei
发明人： Hyo-Joong Kim , Steven A Benner , Ion Mircesti Scorei
IPC分类号： C07H19/048 , C07H1/02
摘要： Nicotinamide ribose has many applications, including as a dietary supplement. This invention convers a process to prepare nicotinamide ribose it in its phosphorylated form. The instant invention is based on the discovery that nicotinamide ribose phosphate emerges in stable form by direct reaction of ribose-1,2-cyclic phosphate. It is based on the further conversion of the phosphorylated nicotinamide ribose product to unphosphorylated nicotinamide ribose upon treatment with an enzymatic phosphatase, most preferably in buffer containing borate. It is based on the further discovery that compositions of nicotinamide ribose with borate slow the decomposition of nicotinamide ribose, and therefore is more useful than compositions of nicotinamide ribose without borate.

5. 发明申请

US20090117380A1 Filament Bundle Type Nano Fiber and Manufacturing Method Thereof 审中-公开
标题翻译：丝束束式纳米纤维及其制造方法
公开(公告)号：US20090117380A1
公开(公告)日：2009-05-07
申请号：US11920495
申请日：2006-05-15
申请人： Jae-Rock Lee , Seung-Yong Jee , Hyo-Joong Kim , Young-Taik Hong , Seok Kim , Soo-Jin Park
发明人： Jae-Rock Lee , Seung-Yong Jee , Hyo-Joong Kim , Young-Taik Hong , Seok Kim , Soo-Jin Park
IPC分类号： D02G3/02 , B29C47/88
CPC分类号： D01D5/0076 , D01F6/80 , D01F6/90 , Y10T428/29 , Y10T428/2913 , Y10T428/2929 , Y10T428/298
摘要： A filament type nano-sized long fiber and a method of producing the same. In the method, a spinning solution or a spinning melt is electro-spun in drops using a spinneret to which a critical voltage is applied, and the spun drops are continuously collected on a multi-collector. The spinning solution is produced by dissolving a blend or copolymer consisting of two or more kinds of polymers in a solvent. The spinning melt is produced by melting the polymers. The multi-collector is selected from the group consisting of a plate type collector, a roll type collector, and a combination thereof. The filament type nano-sized long fiber is processed into a yarn through one step during the electrospinning process, and thus, mechanical properties are better than those of a conventional nanofiber non-woven fabric. Consequently, the filament type nano-sized long fiber can be utilized for the extended application.
摘要翻译：长丝型纳米长纤维及其制造方法。在该方法中，使用施加有临界电压的喷丝头，将纺丝溶液或纺丝熔体以液滴电纺丝，并将纺丝液滴连续收集在多收集器上。纺丝溶液通过将由两种或更多种聚合物组成的共混物或共聚物溶解在溶剂中来制备。通过熔化聚合物制备纺丝熔体。多集电体选自板式集电体，辊式集电体及其组合。丝网型纳米长纤维在静电纺丝过程中通过一步加工成纱线，因此机械性能优于常规纳米纤维无纺布。因此，长丝型纳米尺寸长纤维可用于扩展应用。

6. 发明授权

US5843410A Polymeric ultraviolet screening agent and process for the preparation thereof 失效
标题翻译：聚合紫外线屏蔽剂及其制备方法
公开(公告)号：US5843410A
公开(公告)日：1998-12-01
申请号：US755662
申请日：1996-11-25
申请人： Hyo-Joong Kim , Jong-Tae Lee , Se-Hoon Kang
发明人： Hyo-Joong Kim , Jong-Tae Lee , Se-Hoon Kang
IPC分类号： C09K3/00 , A61K8/00 , A61K8/368 , A61K8/81 , A61Q17/00 , A61Q17/04 , C08F8/00 , C08F12/00 , C08F12/22 , C08F12/32 , A61K7/42 , A61K7/00 , A61K31/74
CPC分类号： C08F12/32 , A61K8/8123 , A61Q17/04
摘要： The present invention relates to a novel polymeric ultraviolet(UV) screening agent comprising at least one monomer represented by the following formula (I) in the molecule: ##STR1## in which X represents the following formula (II) or (III), ##STR2## wherein R represents C.sub.1 -C.sub.12 alkyl or C.sub.3 -C.sub.12 cycloalkyl which can be optionally substituted by C.sub.1 -C.sub.6 alkyl, and to a process for preparing the same.
摘要翻译：本发明涉及分子中包含至少一种由下式（I）表示的单体的新型聚合物紫外线（UV）筛选剂：其中X表示下式（II）或（III ）可以任选被C 1 -C 6烷基取代的C 1 -C 12烷基或C 3 -C 12环烷基，及其制备方法。

7. 发明申请

US20090270431A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections 审中-公开
标题翻译：环戊烯醇核苷化合物的合成中间体和治疗病毒感染的方法
公开(公告)号：US20090270431A1
公开(公告)日：2009-10-29
申请号：US12083571
申请日：2006-10-19
申请人： David C.K. Chu , Jong Hyun Cho , Hyo-Joong Kim
发明人： David C.K. Chu , Jong Hyun Cho , Hyo-Joong Kim
IPC分类号： A61K31/519 , C07D249/04 , A61K31/4192 , A61K31/437 , C07D471/04 , C07D487/04 , A61P31/12
CPC分类号： C07D487/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20
摘要： The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR1, with the proviso that when A′ is OR, A is H; and when A is OR2, A′ is H; X is C—R3 or N; Y is C—R3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R3 is H or C1-C3 alkyl; D is H or NHR2; E is absent or H; G is O or NHR2; J is N or C—R4; K is N or C—H; R4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH2, NH2, NO2, —C═C—H (cis or trans) or —C≡C—H; Ra is H or CH3; Each R1 is independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R2 is independently H, an acyl group, a C1-C20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.
摘要翻译：本发明涉及根据结构（I）的化合物，其中B为式（Ia），式（Ib）或式（Ic）; A是H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）; A'是H，OR 2或卤素（F，Cl，Br，I，优选F或Br，更优选F）; A“为H或OR 1，条件是当A'为OR时，A为H; 当A为OR2时，A'为H; X为C-R3或N; Y为C-R3或N; 优选X或Y为N，X和Y不同时为N; R3是H或C1-C3烷基; D是H或NHR 2; E不存在或H; G为O或NHR 2; J为N或C-R4; K为N或C-H; R4是H，卤素（F，Cl，Br，I），CN，-C（-O）NH2，NH2，NO2，-C-C-H（顺式或反式）或-C≡C-H; Ra为H或CH3; 每个R 1独立地是H，酰基，C 1 -C 20烷基或醚基，磷酸酯，二磷酸酯，三磷酸酯，磷酸二酯基团; 每个R 2独立地为H，酰基，C 1 -C 20烷基或醚基; 和其药学上可接受的盐，溶剂化物或多晶型物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式